As of November 9, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Fulcrum Therapeutics, Inc. The largest reported stake is Tang Capital Management, LLC's, at 10.4%. 21 filings are on record since August 12, 2025 (Schedule 13G/A, July 15, 2026).
Sell to companies like Fulcrum Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Bank Of America Corp · Sole voting: 0 · Shared voting: 1,114,867 · Sole dispositive: 0 · Shared dispositive: 1,114,867 · SCHEDULE 13G/A, 2026-10-28
- · Reporting person: BlackRock Portfolio Management LLC · Sole voting: 5,436,791 · Shared voting: 0 · Sole dispositive: 6,155,437 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-27
- · Reporting person: Nantahala Capital Management, LLC · Sole voting: 0 · Shared voting: 5,475,040 · Sole dispositive: 0 · Shared dispositive: 5,475,040 · SCHEDULE 13G, 2026-08-14
- · Reporting person: Montanova Capital, LLC · Sole voting: 0 · Shared voting: 3,680,921 · Sole dispositive: 0 · Shared dispositive: 3,680,921 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
Fulcrum Therapeutics, Inc. has 21 Schedule 13D or 13G filings on record since 2025-08-12. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: about 57 jobs, latest 2026-06-04 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Tang Capital Management, LLC | 10.4% | 6,913,329 | SCHEDULE 13G/A, 2026-07-15 | 2026-07-13 |
| EcoR1 Capital, LLC | 9% | 6,000,000 | SCHEDULE 13G, 2026-06-25 | 2026-06-17 |
| Nantahala Capital Management, LLC | 8.22% | 5,475,040 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| BlackRock Portfolio Management LLC | 8.1% | 6,155,437 | SCHEDULE 13G/A, 2026-10-27 | 2026-09-30 |
| BlackRock, Inc. | 7.2% | 4,802,880 | SCHEDULE 13G/A, 2026-07-28 | 2026-06-30 |
| Montanova Capital, LLC | 5.5% | 3,680,921 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Adage Capital Management, L.P. | 4.5% | 2,432,000 | SCHEDULE 13G/A, 2025-11-13 | 2025-09-30 |
| Bank Of America Corp | 1.5% | 1,114,867 | SCHEDULE 13G/A, 2026-10-28 | 2026-09-30 |
| RA Capital Management, L.P. | 0% | 0 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
| TCG Crossover GP II, LLC | 0% | 0 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Fulcrum Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Fulcrum Therapeutics, Inc. and the records around it.
Fulcrum Therapeutics, Inc. elsewhere on the record
- Leadership changes Aug 2026
- Layoff notices Jun 2026
- Who owns it
Companies that share a holder
- EcoR1 Capital, LLC also filed stake reports on 20 other companies: Mereo BioPharma Group plc (Aug 2026), Alto Neuroscience, Inc. (Jul 2026), Eloxx Pharmaceuticals, Inc. (Jun 2026)
- TCG Crossover GP II, LLC also filed stake reports on 21 other companies: ALX Oncology Holdings Inc. (Aug 2026), First Tracks Biotherapeutics, Inc. (Aug 2026), LB Pharmaceuticals Inc. (Aug 2026)
- Montanova Capital, LLC also filed stake reports on 22 other companies: Veradermics, Inc (Aug 2026), Abeona Therapeutics Inc. (Aug 2026), InflaRx N.V. (Aug 2026)
Watch Fulcrum Therapeutics, Inc.
Get an email when Fulcrum Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Fulcrum Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Fulcrum Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Fulcrum Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
25 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Tang Capital Management, LLC | 0 | 6,913,329 | 0 | 6,913,329 | SCHEDULE 13G/A, 2026-07-15 |
| Kevin Tang | 0 | 6,913,329 | 0 | 6,913,329 | SCHEDULE 13G/A, 2026-07-15 |
| Tang Capital Partners, LP | 0 | 1,630,142 | 0 | 1,630,142 | SCHEDULE 13G/A, 2026-07-15 |
| Tang Capital Partners International, LP | 0 | 2,160,423 | 0 | 2,160,423 | SCHEDULE 13G/A, 2026-07-15 |
| Tang Capital Partners Iii, Inc | 0 | 1,630,127 | 0 | 1,630,127 | SCHEDULE 13G/A, 2026-07-15 |
| Tang Capital Partners Iv, Inc | 0 | 1,492,637 | 0 | 1,492,637 | SCHEDULE 13G/A, 2026-07-15 |
| EcoR1 Capital, LLC | 0 | 6,000,000 | 0 | 6,000,000 | SCHEDULE 13G, 2026-06-25 |
| Oleg Nodelman | 0 | 6,000,000 | 0 | 6,000,000 | SCHEDULE 13G, 2026-06-25 |
| EcoR1 Capital Fund Qualified, L.P. | 0 | 5,614,199 | 0 | 5,614,199 | SCHEDULE 13G, 2026-06-25 |
| Nantahala Capital Management, LLC | 0 | 5,475,040 | 0 | 5,475,040 | SCHEDULE 13G, 2026-08-14 |
| Wilmot B. Harkey | 0 | 5,475,040 | 0 | 5,475,040 | SCHEDULE 13G, 2026-08-14 |
| Daniel Mack | 0 | 5,475,040 | 0 | 5,475,040 | SCHEDULE 13G, 2026-08-14 |
| BlackRock Portfolio Management LLC | 5,436,791 | 0 | 6,155,437 | 0 | SCHEDULE 13G/A, 2026-10-27 |
| BlackRock, Inc. | 4,736,507 | 0 | 4,802,880 | 0 | SCHEDULE 13G/A, 2026-07-28 |
| Montanova Capital, LLC | 0 | 3,680,921 | 0 | 3,680,921 | SCHEDULE 13G/A, 2026-08-14 |
| Averill Master Fund, Ltd. | 0 | 2,553,201 | 0 | 2,553,201 | SCHEDULE 13G/A, 2026-08-14 |
| Aaron Cowen | 0 | 3,680,921 | 0 | 3,680,921 | SCHEDULE 13G/A, 2026-08-14 |
| Bank Of America Corp | 0 | 1,114,867 | 0 | 1,114,867 | SCHEDULE 13G/A, 2026-10-28 |
| RA Capital Management, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Peter Kolchinsky | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Rajeev Shah | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| RA Capital Healthcare Fund, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| TCG Crossover GP II, LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| TCG Crossover Fund II, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Fulcrum Therapeutics, Inc. by CUSIP 359616109 and gives its principal executive office as 26 LANDSDOWNE STREET, CAMBRIDGE, MA 02139 (SCHEDULE 13G/A, 2026-10-28).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-12 | Adage Capital Management, L.P. | 8.5% | SCHEDULE 13G/A |
| 2025-10-17 | BlackRock, Inc. | 6% | SCHEDULE 13G/A |
| 2025-11-13 | Adage Capital Management, L.P. | 4.5% | SCHEDULE 13G/A |
| 2025-12-10 | RA Capital Management, L.P. | 11.2% | SCHEDULE 13G/A |
| 2026-02-17 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-15 | Nantahala Capital Management, LLC | 4.58% | SCHEDULE 13G/A |
| 2026-05-15 | TCG Crossover GP II, LLC | 7.9% | SCHEDULE 13G/A |
| 2026-06-10 | Tang Capital Management, LLC | 8.2% | SCHEDULE 13G |
| 2026-06-25 | EcoR1 Capital, LLC | 9% | SCHEDULE 13G |
| 2026-06-25 | EcoR1 Capital, LLC | 9% | SCHEDULE 13G |
| 2026-07-15 | Tang Capital Management, LLC | 10.4% | SCHEDULE 13G/A |
| 2026-07-17 | BlackRock Portfolio Management LLC | 6% | SCHEDULE 13G |
| 2026-07-28 | BlackRock, Inc. | 7.2% | SCHEDULE 13G/A |
| 2026-08-03 | Bank Of America Corp | 6.7% | SCHEDULE 13G |
| 2026-08-14 | Montanova Capital, LLC | 5.5% | SCHEDULE 13G/A |
| 2026-08-14 | Nantahala Capital Management, LLC | 8.22% | SCHEDULE 13G |
| 2026-08-14 | TCG Crossover GP II, LLC | 0% | SCHEDULE 13G/A |
| 2026-08-14 | RA Capital Management, L.P. | 0% | SCHEDULE 13G/A |
| 2026-10-27 | BlackRock Portfolio Management LLC | 8.1% | SCHEDULE 13G/A |
| 2026-10-28 | Bank Of America Corp | 1.5% | SCHEDULE 13G/A |
Questions about who owns Fulcrum Therapeutics, Inc.
Who owns Fulcrum Therapeutics, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Fulcrum Therapeutics, Inc.: Tang Capital Management, LLC (10.4%, Schedule 13G/A, filed 2026-07-15), EcoR1 Capital, LLC (9%, Schedule 13G, filed 2026-06-25), Nantahala Capital Management, LLC (8.22%, Schedule 13G, filed 2026-08-14), BlackRock Portfolio Management LLC (8.1%, Schedule 13G/A, filed 2026-10-27) and BlackRock, Inc. (7.2%, Schedule 13G/A, filed 2026-07-28); 1 more is listed above.
Who are the largest shareholders of Fulcrum Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Fulcrum Therapeutics, Inc. on this page are Tang Capital Management, LLC (10.4%), EcoR1 Capital, LLC (9%) and Nantahala Capital Management, LLC (8.22%).
When did Tang Capital Management, LLC buy into Fulcrum Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Tang Capital Management, LLC on this page is the Schedule 13G, filed 2026-06-10, reporting 8.2%; its latest, Schedule 13G/A filed 2026-07-15, reports 10.4%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 21 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Fulcrum Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 10, 2026 | Leadership change: Alan Musso appointed | — | Leadership changes | Source |
| June 11, 2026 | Leadership change: Greg Tourangeau departs, Vice President, Finance | — | Leadership changes | Source |
| April 27, 2026 | Leadership change: Josh Lehrer appointed, Director, and 2 more | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Fulcrum Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.